Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Humalog ® (insulin lispro)
Humalog® Mix25/Mix50 (insulin lispro): Posology and method of administration
The dosage should be determined by the physician, according to the requirement of the patient
The dosage should be determined by the physician, according to the requirement of the patient.
Humalog Mix25 and Humalog Mix50 may be given shortly before meals. When necessary, Humalog Mix25 and Humalog Mix50 can be given soon after meals. Humalog Mix25 and Humalog Mix50 should only be given by subcutaneous injection. Under no circumstances should Humalog Mix25 or Humalog Mix50 be given intravenously.
The rapid onset and early peak of activity of Humalog itself is observed following the subcutaneous administration of Humalog Mix25 and Humalog Mix50. This allows Humalog Mix25 and Humalog Mix50 to be given very close to mealtime. The duration of action of the insulin lispro protamine suspension component of Humalog Mix25 and Humalog Mix50 is similar to that of a basal insulin (NPH [isophane]).
The time course of action of any insulin may vary considerably in different individuals or at different times in the same individual. As with all insulin preparations, the duration of action of Humalog Mix25 and Humalog Mix50 is dependent on dose, site of injection, blood supply, temperature, and physical activity.
Insulin requirements may be reduced in the presence of renal impairment.
Insulin requirements may be reduced in patients with hepatic impairment due to reduced capacity for gluconeogenesis and reduced insulin breakdown; however, in patients with chronic hepatic impairment, an increase in insulin resistance may lead to increased insulin requirements.
Administration of Humalog Mix25 or Humalog Mix50 to children below 12 years of age should be considered only in case of an expected benefit when compared to soluble insulin.
Method of administration
Subcutaneous administration should be in the upper arms, thighs, buttocks, or abdomen. Use of injection sites should be rotated so that the same site is not used more than approximately once a month, in order to reduce the risk of lipodystrophy and cutaneous amyloidosis.
When administered subcutaneously care should be taken when injecting Humalog Mix25 or Humalog Mix50 to ensure that a blood vessel has not been entered. After injection, the site of injection should not be massaged. Patients must be educated to use the proper injection techniques.
The KwikPen delivers 1 – 60 units in steps of 1 unit in a single injection. The needed dose is dialled in units. The number of units is shown in the dose window of the pen.
Humalog Mix 25 [Summary of Product Characteristics]. Utrecht, The Netherlands: Eli Lilly Nederland B.V.
Humalog Mix 50 [Summary of Product Characteristics]. Utrecht, The Netherlands: Eli Lilly Nederland B.V.
Date of Last Review: September 22, 2020